Karyopharm Therapeutics (KPTI) Tax Provisions (2017 - 2025)
Karyopharm Therapeutics (KPTI) reported Tax Provisions of -$67000.0 for Q4 2025, up 38.53% on a YoY basis from -$48364.2 in Q4 2024, and down 297.06% quarter-over-quarter from $34000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Tax Provisions (2017 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Tax Provisions for 9 years, with the latest figure at -$67000.0 in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions rose 38.53% year-over-year to -$67000.0; the trailing twelve-month figure through Dec 2025 stood at $43000.0 (down 24.56% YoY), and the FY2025 full-year result was $43000.0, down 24.56% from the prior year.
- Tax Provisions for Q4 2025 stood at -$67000.0, down from $34000.0 in the prior quarter.
- The five-year high for Tax Provisions was $149000.0 in Q1 2021, with the low at -$121000.0 in Q4 2021.
- Historically, Tax Provisions has averaged $51850.0 across 5 years, with a median of $60500.0 in 2023.
- Annual changes were most pronounced in 2021 — Tax Provisions sank 295.16% — and 2022, when it jumped 160.33%.
- Karyopharm Therapeutics' Tax Provisions stood at -$121000.0 in 2021, then jumped by 160.33% to $73000.0 in 2022, then surged by 46.58% to $107000.0 in 2023, then slumped by 201.87% to -$109000.0 in 2024, then jumped by 38.53% to -$67000.0 in 2025.
- The last three Tax Provisions figures came in at -$67000.0 (Q4 2025), $34000.0 (Q3 2025), and $40000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -859,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 216,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | -67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -67,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | -109,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 71,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 127,000.00 |
| Mar 31, 2023 | 54,000.00 |
| Dec 31, 2022 | 73,000.00 |
| Sep 30, 2022 | 45,000.00 |
| Jun 30, 2022 | 121,000.00 |
| Mar 31, 2022 | 130,000.00 |
| Dec 31, 2021 | -121,000.00 |
| Sep 30, 2021 | 106,000.00 |
| Jun 30, 2021 | 134,000.00 |
| Mar 31, 2021 | 149,000.00 |